2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs

• Published in: Bioanalysis 2019-12, Vol.11 (23), p.2099-2132
• Main Authors: Booth, Brian, Stevenson, Lauren, Pillutla, Renuka, Buonarati, Michael, Beaver, Chris, Fraier, Daniela, Garofolo, Fabio, Haidar, Sam, Islam, Rafiq, James, Christopher, Kadavil, John, Kavetska, Olga, Li, Fumin, Satterwhite, Christina, Savoie, Natasha, Subramaniam, Sriram, Tampal, Nilufer, Thway, Theingi, Woolf, Eric, Blaye, Olivier Le, Andisik, Matthew, Briscoe, Chad, Cape, Stephanie, Dasgupta, Arindam, Fischer, Sally, Hayes, Roger, Kamerud, John, Lima Santos, Gustavo Mendes, Nehls, Corey, Soo, Catherine, Vinter, Stephen, Whale, Emma, Xu, Keyang, Cho, Seongeun (Julia), Edmison, Anna, Kassim, Sean, Rocha, Thais Correa, Welink, Jan, Amur, Shashi, Bandukwala, Abbas, Cherry, Elana, Hopper, Shirley, Ishii-Watabe, Akiko, Kirshner, Susan, Maher, Kevin, Pedras-Vasconcelos, Joao, Saito, Yoshiro, Saunders, Therese Solstad, Skibeli, Venke, Verthelyi, Daniela, Wang, Yow-Ming, Yan, Haoheng
• Format: Article
• Language: English
• Subjects: Antibodies; Biomarkers; Biotechnology; Flow cytometry; Gene therapy; Immunogenicity; Mass spectrometry; Mass spectroscopy; Oligonucleotides; Pharmaceuticals; Product development; Regulatory agencies; Scientific imaging
• ISSN: 1757-6180; 1757-6199
• DOI: 10.4155/bio-2019-0270

The 2019 13 Workshop on Recent Issues in Bioanalysis (WRIB) took place in New Orleans, LA on 1–5 April 2019 with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, week-long event – a full immersion week of bioanalysis, biomarkers, immunogenicity and gene therapy. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small- and large-molecule bioanalysis involving LCMS, hybrid LBA/LCMS, LBA cell-based/flow cytometry assays and qPCR approaches. This 2019 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2019 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 2) covers the recommendations on the 2018 FDA BMV guidance, 2019 ICH M10 BMV draft guideline and regulatory agencies' input on bioanalysis, biomarkers, immunogenicity and gene therapy. Part 1 (Innovation in small molecules and oligonucleotides and mass spectrometry method development strategies for large molecules bioanalysis) and Part 3 (New insights in biomarker assay validation, current and effective strategies for critical reagent management, flow cytometry validation in drug discovery and development and CLSI H62, interpretation of the 2019 FDA immunogenicity guidance and gene therapy bioanalytical challenges) are published in volume 10 of , issues 22 and 24 (2019), respectively.